DK0700680T3 - Gepirone-dosisform - Google Patents

Gepirone-dosisform

Info

Publication number: DK0700680T3
Authority: DK; Denmark
Prior art keywords: dosage form; gepirone; colourant; pref; hydroxypropylmethylcellulose
Prior art date: 1994-09-06

Application number

DK95113476T

Other languages

English (en)

Inventor

Stephen T David

Joseph C H Chou

Claude E Gallian

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-06

Filing date

1995-08-28

Publication date

2000-05-01

1995-08-28 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2000-05-01 Application granted granted Critical

2000-05-01 Publication of DK0700680T3 publication Critical patent/DK0700680T3/da

Links

239000002552 dosage form Substances 0.000 title abstract 2
QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 title abstract 2
229960000647 gepirone Drugs 0.000 title abstract 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
238000010521 absorption reaction Methods 0.000 abstract 1
239000008119 colloidal silica Substances 0.000 abstract 1
238000013265 extended release Methods 0.000 abstract 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
235000019359 magnesium stearate Nutrition 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
239000008108 microcrystalline cellulose Substances 0.000 abstract 1
229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Electroluminescent Light Sources (AREA)
Adhesives Or Adhesive Processes (AREA)

DK95113476T 1994-09-06 1995-08-28 Gepirone-dosisform DK0700680T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/301,281 US5478572A (en)	1994-09-06	1994-09-06	Gepirone dosage form

Publications (1)

Publication Number	Publication Date
DK0700680T3 true DK0700680T3 (da)	2000-05-01

Family

ID=23162703

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95113476T DK0700680T3 (da)	1994-09-06	1995-08-28	Gepirone-dosisform

Country Status (24)

Country	Link
US (1)	US5478572A (da)
EP (1)	EP0700680B1 (da)
JP (1)	JP4540756B2 (da)
KR (1)	KR100380806B1 (da)
CN (1)	CN1096858C (da)
AT (1)	ATE186462T1 (da)
AU (1)	AU702282B2 (da)
CA (1)	CA2157323C (da)
CY (1)	CY2222B1 (da)
CZ (1)	CZ286417B6 (da)
DE (1)	DE69513254T2 (da)
DK (1)	DK0700680T3 (da)
ES (1)	ES2142432T3 (da)
FI (1)	FI117319B (da)
GR (1)	GR3032598T3 (da)
HU (1)	HU227339B1 (da)
IL (1)	IL114984A (da)
NO (1)	NO307814B1 (da)
NZ (1)	NZ272855A (da)
PL (1)	PL180691B1 (da)
RU (1)	RU2155044C2 (da)
SG (1)	SG30436A1 (da)
TW (1)	TW445152B (da)
ZA (1)	ZA957144B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030215507A1 (en) *	1996-03-25	2003-11-20	Wyeth	Extended release formulation
US20060068018A1 (en) *	1996-03-25	2006-03-30	Wyeth	Extended release formulation
GB9706089D0 (en) *	1997-03-24	1997-05-14	Scherer Ltd R P	Pharmaceutical composition
US20040023948A1 (en) *	1997-03-24	2004-02-05	Green Richard David	Fast-dispersing dosage form containing 5-HT1 agonists
US5895663A (en) *	1997-07-31	1999-04-20	L. Perrigo Company	Pseudoephedrine hydrochloride extended-release tablets
CN100367965C (zh) *	1999-12-20	2008-02-13	法布瑞－克雷默制药有限公司	吉吡隆代谢物在制备改善哺乳动物不良心理状态的组合物上的应用
US6534507B1 (en)	1999-12-20	2003-03-18	Fabre-Kramer Pharmaceuticals, Inc.	Methods for treating psychological disorders using bioactive metabolites of gepirone
KR20040018314A (ko) *	2000-12-08	2004-03-03	악조 노벨 엔.브이.	게피론을 함유하는 경구 투여용 연장 방출형 제제
AP2003002900A0 (en)	2001-05-01	2003-12-31	Pfizer Prod Inc	Method for manufacturing a low dose pharmaceutical composition
PE20030527A1 (es) *	2001-10-24	2003-07-26	Gruenenthal Chemie	Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030152621A1 (en) *	2001-11-21	2003-08-14	Egberink J. G. J.	Pharmaceutical formulation of gepirone for oral administration
TW200306866A (en) *	2002-05-07	2003-12-01	Akzo Nobel Nv	A method to improve surface properties of pharmaceutical tablets
US20060134193A1 (en) *	2002-09-24	2006-06-22	Pieter De Haan	Method to improve pharmaceutical tablets having a matrix of cellulose ether
CN1819821B (zh)	2003-08-08	2010-10-13	拜奥维尔实验室国际股份有限公司	盐酸安非他酮的改良释放片剂
AR048112A1 (es) *	2004-03-25	2006-03-29	Solvay Pharm Bv	Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
AR049478A1 (es) *	2004-03-25	2006-08-09	Solvay Pharm Bv	Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
US7444197B2 (en)	2004-05-06	2008-10-28	Smp Logic Systems Llc	Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
US7799273B2 (en)	2004-05-06	2010-09-21	Smp Logic Systems Llc	Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US20060013874A1 (en) *	2004-07-15	2006-01-19	Solvay Pharmaceuticals B.V.	Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one
EP1781292B1 (en) *	2004-07-15	2010-09-22	Abbott Healthcare Products B.V.	Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one
WO2006052227A1 (en) *	2004-11-05	2006-05-18	Fabre-Kramer Holdings, Inc.	High-dosage extended-release formulation of gepirone
US20060099267A1 (en) *	2004-11-05	2006-05-11	Fabre-Kramer Pharmaceuticals, Inc.	High-dosage extended-release formulation of gepirone
DK2168585T3 (da) *	2005-06-09	2012-02-27	Euro Celtique Sa	Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3870790A (en) *	1970-01-22	1975-03-11	Forest Laboratories	Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1405088A (en) *	1971-06-03	1975-09-03	Mundipharma Ag	Slow release formulation
US3965256A (en) *	1972-05-16	1976-06-22	Synergistics	Slow release pharmaceutical compositions
US4226849A (en) *	1979-06-14	1980-10-07	Forest Laboratories Inc.	Sustained release therapeutic compositions
US4357469A (en) *	1979-06-14	1982-11-02	Forest Laboratories, Inc.	Carrier base material for prolonged release therapeutic compositions
US4309406A (en) *	1979-07-10	1982-01-05	American Home Products Corporation	Sustained release pharmaceutical compositions
US4248856A (en) *	1979-07-10	1981-02-03	American Home Products Corporation	Sustained release pharmaceutical compositions
US4248858A (en) *	1979-08-09	1981-02-03	American Home Products Corporation	Sustained release pharmaceutical compositions
US4547358A (en) *	1980-05-06	1985-10-15	Mead Johnson & Company	Sustained release tablet containing at least 95 percent theophylline
US4369172A (en) *	1981-12-18	1983-01-18	Forest Laboratories Inc.	Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4423049A (en) *	1981-12-28	1983-12-27	Mead Johnson & Company	2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4389393A (en) *	1982-03-26	1983-06-21	Forest Laboratories, Inc.	Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4415547A (en) *	1982-06-14	1983-11-15	Sterling Drug Inc.	Sustained-release pharmaceutical tablet and process for preparation thereof
US4704284A (en) *	1982-08-12	1987-11-03	Pfizer Inc.	Long-acting matrix tablet formulations
US4690824A (en) *	1983-07-07	1987-09-01	Redi-Rowell, Inc.	Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4610870A (en) *	1984-10-05	1986-09-09	E. R. Squibb & Sons, Inc.	Controlled release formulation
US4695591A (en) *	1985-03-29	1987-09-22	Schering Corporation	Controlled release dosage forms comprising hydroxypropylmethylcellulose
SE460947B (sv) *	1986-08-26	1989-12-11	Lejus Medical Ab	En multiple-unit-dos komposition av l-dopa
US4771053A (en) *	1987-03-02	1988-09-13	Bristol-Myers Company	Method for alleviation of primary depressive disorders
US4782060A (en) *	1987-07-29	1988-11-01	Bristol-Myers Company	Gepirone for alleviation of panic disorders
SE8703881D0 (sv) *	1987-10-08	1987-10-08	Haessle Ab	New pharmaceutical preparation
SE8704097D0 (sv) *	1987-10-22	1987-10-22	Astra Ab	Oral formulation of buspirone and salts thereof
US5106849A (en) *	1988-05-24	1992-04-21	American Home Products Corporation	Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
US5096908A (en) *	1990-05-04	1992-03-17	Eli Lilly And Company	Method of inhibiting gastric acid secretion
US5189179A (en) *	1990-08-29	1993-02-23	Merrell Dow Pharmaceuticals Inc.	Serotonin 5ht1a agonists
US5124346A (en) *	1991-04-23	1992-06-23	Pfizer Inc.	Synergistic combinations in the treatment of anxiety
US5169638A (en) *	1991-10-23	1992-12-08	E. R. Squibb & Sons, Inc.	Buoyant controlled release powder formulation
US5292766A (en) *	1992-03-25	1994-03-08	Eli Lilly And Company	Method for improving primary memory and/or learning
US5378846A (en) *	1993-06-11	1995-01-03	Russian-American Institute For New Drug Development	1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

1994
- 1994-09-06 US US08/301,281 patent/US5478572A/en not_active Expired - Lifetime
1995
- 1995-08-16 NO NO953212A patent/NO307814B1/no not_active IP Right Cessation
- 1995-08-16 TW TW084108546A patent/TW445152B/zh active
- 1995-08-17 IL IL11498495A patent/IL114984A/xx not_active IP Right Cessation
- 1995-08-25 NZ NZ272855A patent/NZ272855A/en not_active IP Right Cessation
- 1995-08-25 ZA ZA957144A patent/ZA957144B/xx unknown
- 1995-08-28 DK DK95113476T patent/DK0700680T3/da active
- 1995-08-28 ES ES95113476T patent/ES2142432T3/es not_active Expired - Lifetime
- 1995-08-28 EP EP95113476A patent/EP0700680B1/en not_active Expired - Lifetime
- 1995-08-28 AT AT95113476T patent/ATE186462T1/de active
- 1995-08-28 DE DE69513254T patent/DE69513254T2/de not_active Expired - Lifetime
- 1995-08-31 CA CA002157323A patent/CA2157323C/en not_active Expired - Lifetime
- 1995-09-04 SG SG1995001280A patent/SG30436A1/en unknown
- 1995-09-04 KR KR1019950028717A patent/KR100380806B1/ko not_active Expired - Lifetime
- 1995-09-05 AU AU30438/95A patent/AU702282B2/en not_active Ceased
- 1995-09-05 CN CN95116203A patent/CN1096858C/zh not_active Expired - Fee Related
- 1995-09-05 RU RU95114742/14A patent/RU2155044C2/ru not_active IP Right Cessation
- 1995-09-05 JP JP22691095A patent/JP4540756B2/ja not_active Expired - Lifetime
- 1995-09-05 FI FI954154A patent/FI117319B/fi not_active IP Right Cessation
- 1995-09-05 HU HU9502599A patent/HU227339B1/hu not_active IP Right Cessation
- 1995-09-05 CZ CZ19952275A patent/CZ286417B6/cs not_active IP Right Cessation
- 1995-09-06 PL PL95310298A patent/PL180691B1/pl not_active IP Right Cessation
2000
- 2000-02-09 GR GR20000400296T patent/GR3032598T3/el unknown
2001
- 2001-05-04 CY CY0100008A patent/CY2222B1/xx unknown

Also Published As

Publication number	Publication date
FI954154L (fi)	1996-03-07
FI954154A0 (fi)	1995-09-05
GR3032598T3 (en)	2000-05-31
CN1096858C (zh)	2002-12-25
ATE186462T1 (de)	1999-11-15
KR100380806B1 (ko)	2003-07-10
US5478572A (en)	1995-12-26
CA2157323C (en)	2004-01-20
HU9502599D0 (en)	1995-11-28
PL180691B1 (en)	2001-03-30
ES2142432T3 (es)	2000-04-16
TW445152B (en)	2001-07-11
NZ272855A (en)	1997-05-26
JPH08183736A (ja)	1996-07-16
AU702282B2 (en)	1999-02-18
HK1014666A1 (en)	1999-09-30
EP0700680B1 (en)	1999-11-10
CN1128142A (zh)	1996-08-07
CZ286417B6 (en)	2000-04-12
PL310298A1 (en)	1996-03-18
SG30436A1 (en)	1996-06-01
DE69513254T2 (de)	2000-06-15
IL114984A (en)	1999-10-28
ZA957144B (en)	1996-03-26
IL114984A0 (en)	1995-12-08
NO953212D0 (no)	1995-08-16
NO953212L (no)	1996-03-07
CZ227595A3 (en)	1996-03-13
DE69513254D1 (de)	1999-12-16
HU227339B1 (en)	2011-04-28
AU3043895A (en)	1996-03-21
JP4540756B2 (ja)	2010-09-08
FI117319B (fi)	2006-09-15
CA2157323A1 (en)	1996-03-07
NO307814B1 (no)	2000-06-05
KR960010007A (ko)	1996-04-20
RU2155044C2 (ru)	2000-08-27
CY2222B1 (en)	2003-04-18
HUT73182A (en)	1996-06-28
EP0700680A1 (en)	1996-03-13

Publication	Publication Date	Title
FI954154A0 (fi)	1995-09-05	Gepiroonikoostumuksia
NO20065390L (no)	1997-10-28	Farmasoytisk preparat i fast enhetsdoseringsform
AU646399B2 (en)	1994-02-24	Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
BG101901A (bg)	1998-10-30	2-метил-тиено-бензодиазепинова формулировка за приемане през устата и метод за нейното получаване
AR016827A1 (es)	2001-08-01	PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
ATE100708T1 (de)	1994-02-15	Unbeschichtete pharmazeutische reaktionstablette.
CA2382387A1 (en)	2001-03-08	Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
BR9708772A (pt)	2000-01-04	"comprimidos famacêuticos de liberação controlada que contém um veìculo à base de amilose reticulada e hidróxi propil metil celulose"
NO971361L (no)	1997-05-21	Fremgangsmåte for fremstilling av doseringsenheter ved våtgranulering
EA200001201A2 (ru)	2001-08-27	Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
AU2793989A (en)	1989-06-14	Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
FI932552A0 (fi)	1993-06-04	Foerfarande foer framstaellning av en fast enhet doseringsform foer reglerad utloesningen
SE8901003L (sv)	1989-09-26	Snabbloesliga preparat
NO954952L (no)	1995-12-06	Fremgangsmåte for fremstilling av en oral fast-stoff doseringsform som inneholder diklofenac
HUP9801686A2 (hu)	1999-06-28	Amino-tetralin-származék alkalmazása kardiovaszkuláris megbetegedések terápiájában használható gyógyszer előállítására
KR930021206A (ko)	1993-11-22	시타라빈 옥포스페이트 경질 캡슐제
AU4898790A (en)	1990-08-09	An erosion-controlled release system for active agents and a process for its preparation
KR960003718A (ko)	1996-02-23	말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
UA50814C2 (uk)	2002-11-15	Анальгетичний лікарський засіб
BRPI0315657B8 (pt)	2021-05-25	formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição
MX9706361A (es)	1998-07-31	Sales de carboxiamidas estables, de accion prolongada, composiciones que las contienen y el uso de las mismas.
BG103023A (en)	2000-06-30	Bronchodilatation medicamentous form
YU28404A (sh)	2006-08-17	Brzo topljiva formulacija za oralno doziranje